Diabetes mellitus (DM) is a disease of epidemic proportions. Asia harbours 60% of the global DM population (4.7 billion) (PMID 27502121). Cardiovascular diseases (CVD) account for more than half the mortality and morbidity among patients with DM (WHO 2017). Our previous work from ASIAN-HF Registry revealed that Asian patients with heart failure are predisposed towards a unique lean-diabetic (diabetes in absence of high body mass index) (PMID 29584721). and lean-fat (low body mass index with abdominal obesity) (PMID 31550265) phenotypes. Together, these data suggested that visceral obesity could play a central role in cardiac pathology of lean diabetes. Epicardial fat tissue is the visceral fat distributed along the coronary arteries between the pericardium and the myocardium. Increase in epicardial fat is associated with both DM and CV disease.Realising the dismal prognosis of lean diabetic patients with heart failure and the lack of proven therapies to improve their prognosis, the Asian Diabetes Outcome Prevention Trial (ADOPT) was launched. ADOPT is a multinational prospective trial, which aims to identify high-risk diabetic individuals (using elevated blood biomarker NT-proBNP levels) and intensify primary prevention to reduce future cardiovascular events. ADOPT is currently recruiting at 30 sites across Singapore, Malaysia, Taiwan, China, India and United Arab Emirates.Leveraging on the various cores at NHCS and the data/samples collected from the ADOPT trial, we would like to gain further insights into diabetic HF through more detailed cardiometabolic imaging and mechanistic approaches, as detailed below:
Prof Carolyn Lam Dr Chanchal Chandramouli
Asian Diabetes Outcomes Prevention Trial (ADOPT) Among biomarker (N-terminal pro-B-type natriuretic peptide, NT-proBNP-identified high risk type 2 diabetic patients without pre-existing cardiovascular disease, to test if intensive preventive therapy (high dose renin-angiotensin-aldosterone system inhibitors [RAASi], beta-blockade, sodium-glucose co-transporter 2 inhibitors [SGLT2i]) may be associated with reduced cardiovascular events compared to standard of care. This investigator-initiated trial receives support from the National Medical Research Council of Singapore, philanthropic and industry partners
Highlighted in Singapore’s News & Top Stories: Asia-wide study on reducing chances of diabetes patients developing heart disease underway, Singapore News & Top Stories - The Straits Times
Carolyn Lam Expert discussion on latest update on cardiovascular outcome data in diabetes: https://www.youtube.com/watch?v=C8OrAGyYdB4
Money89.3FM Interview of Carolyn Lam and Chanchal Chandramouli on Women, diabetes and cardiovascular diseases: https://www.moneyfm893.sg/guest/prof-carolyn-lam-and-dr-chanchal-chandramouli-national-heart-centre-singapore-nhcs/
CNA938 Interview of Carolyn Lam on ‘Discovery of skinny diabetics in Asian heart failure patients and launch of new multinational clinical trial’ Facebook link to interview extract here
Arresting Heart Disease In Diabetics by Chanchal Chandramouli, Murmurs 30th Oct 2020: https://www.nhcs.com.sg/news/research/arresting-heart-disease-in-diabetics
Channel 8 News Online featuring Dr. Yong Mong Bee on the Study Low-weight Asian diabetic patients with heart failure have higher mortality https://www.8world.com/news/singapore/article/nhcs-heart-disease-1234166
Interview of David Sim on ‘Discovery of skinny diabetics in Asian heart failure patients and launch of new multinational clinical trial https://www.facebook.com/963haofm.anna/videos/364173054741324/
2022 Carolyn Lam was recognized as Expertscape Expert in Obesity
2021 Carolyn Lam Clarivate’s Highly Cited Researcher 2021 in the category of Clinical Medicine https://recognition.webofscience.com/awards/highly-cited/2021/
2021 Chanchal Chandramouli won Young Investigator Award, Heart Failure Seoul for talk titled “Microvascular dysfunction in diabetic heart failure”
2021 Carolyn Lam recognized as a World Expert by Expertscape’s PubMed-based algorithms.Top 0.1% of scholars writing about Heart Failure over the past 10 years. Heart Failure: Worldwide - Expertscape.com
2021 Carolyn Lam - Worldwide CardioDiabetes Board Member, Worldwide Diabetes Foundation
2021 Chanchal Chandramouli - Worldwide CardioDiabetes Junior Board Member, Worldwide Diabetes Foundation
2020 Carolyn Lam Research Group won 2nd prize for SingHealth Duke-NUS Research Team Award 2020 - “Asian neTwork for Translation Research and Cardiovascular Trials (ATTRaCT program)
2019 Carolyn Lam won National Medical Research Council Clinician Scientist Award
2019 A*STAR Awards 2019: Borderless Award (ATTRaCT program; Program director: Carolyn Lam)
2019 Jin Xuanyi *won the Best Research Achievement Award at Heart Failure Seoul
2019 for excellence achieved in scientific session
2019 Dr Go Yun Yun won the “Singhealth Publish Award 2019”
2018 Chia May Fen Yvonne *won 2nd Prize in Singapore Cardiac Society Young Investigator Award
2018 Chanchal Chandramouli won the Early Career Researcher Award for the talk titled “Impact of obesity on heart failure outcomes” at HF Seoul
2018 Chanchal Chandramouli won travel grant of 955€ for European Society of Cardiology Heart Failure Congress
Subscribe to our mailing list to get the updates to your email inbox...